BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile o
Data from Monitoring Untoward Event Form: Actions Taken [CRF 96] Study Description A two-group randomized repeated measures design that examined the efficacy of Project ACCEPT (Adolescents Coping, Con